Statistical analysis of array expression data as applied to the problem of tamoxifen resistance

Journal of the National Cancer Institute

Volumn 91, Issue 5, 1999, Pages 453-459

  Hilsenbeck, Susan G ^a   Friedrichs, William E ^a   Schiff, Rachel ^a   O'Connell, Peter ^a   Hansen, Rhonda K ^a   Osborne, C Kent ^a   Fuqua, Suzanne A W ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN;

ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DENSITOMETRY; DRUG SENSITIVITY; GENE EXPRESSION; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SIMULATION; STATISTICAL ANALYSIS;

EID: 0033518877     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.5.453     Document Type: Article

References (35)

1. Marshall A, Hodgson J. DNA chips: an array of possibilities. Nat Biotechnol 1998;16: 27-31.
2. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, et al. Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat Genet 1996;14:457-60.
3. Welford SM, Gregg J, Chen E, Garrison D, Sorensen PH, Denny CT, et al. Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization. Nucleic Acids Res 1998;26:3059-65.
4. Chang DD, Park NH, Denny CT, Nelson SF, Pe M. Characterization of transformation related genes in oral cancer cells. Oncogene 1998;16:1921-30.
5. Sehgal A, Boynton AL, Young RF, Vermeulen SS, Yonemura KS, Kohler EP, et al. Application of the differential hybridization of Atlas Human expression arrays technique in the identification of differentially expressed genes in human glioblastoma multiforme tumor tissue. J Surg Oncol 1998;67: 234-41.
6. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
7. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A 1996; 93:10614-9.
8. Bezwoda WR, Esser JD, Dansey R, Kessel I, Lange M. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991;68: 867-72.
9. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:71-85.
10. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel P-1 Study. J Natl Cancer Inst 1998; 90:1371-88.
11. Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991;51:105-9.
12. Fuqua SA, Wiltschke C, Castles C, Wolf D, Allred DC. A role for estrogen receptor variants in endocrine resistance. Endocrine-related cancer 1995;2:19-25.
13. Daffada AA, Johnston SR, Smith IE, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer, Cancer Res 1995;55:288-93.
14. Gallacchi P, Schoumacher F, Eppenberger-Castori S, Von Landenberg EM, Kueng W, Eppenberger U, et al. Increased expression of estrogen-receptor exon-5-deletion variant in relapse tissues of human breast cancer. Int J Cancer 1998;79:44-8.
15. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/ antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11: 657-66.
16. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N/CoR or SMRT. Mol Endocrinol 1997; 11:693-705.
17. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 1998;95: 2920-5.
18. Berns EM, van Staveren IL, Klijn JG, Foekens JA. Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat 1998;48: 87-92.
19. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88: 405-15.
20. Lonning E, Lien EA. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Hematol 1995;21:158-93.
21. Thompson AM, Kerr DJ, Steel CM. Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer 1991;63: 609-14.
22. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70.
23. Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, et al. Accessing genetic information with high-density DNA arrays, Science 1996;274:610-4.
24. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985;45:584-90.
25. CLONTECH Laboratories Inc. Atlas™ Human cDNA expression arrays user manual. Palo Alto (CA): CLONTECH Laboratories. Inc; 1997.
26. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
27. Tatsuoka MM, editor. Multivariate analysis: techniques for educational and psychological research. New York (NY): John Wiley & Sons, Inc; 1971. p. 94-149.
28. Venables WN, Ripley BD. Modern applied statistics with S-plus. New York (NY): Springer-Verlag; 1994. p. 203-8.
29. Anderson TW. An introduction to multivariate statistical analysis. New York (NY): John Wiley & Sons, Inc.; 1958. p. 123.
30. Fuqua SA, Benedix MG, Krieg S, Weng CN, Chamness GC, Oesterreich S. Constitutive overexpression of the 27,000 dalton heat shock protein in late passage human breast cancer cells. Breast Cancer Res Treat 1994;32: 177-86.
31. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 1996; 56:3350-8.
32. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996;15:1292-300.
33. Rabindran SK, Giorgi G, Clos J, Wu C. Molecular cloning and expression of a human heat shock factor, HSF1. Proc Natl Acad Sci U S A 1991;88:6906-10.
34. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 1997;17:5338-47.
35. Fujimoto N, Katzenellenbogen BS. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. Mol Endocrinol 1994;8:296-304.